EUCTR2011-002321-22-ES进行中（未招募）1 期
PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM HOUSE DUST MITE ALLERGY - SULGEN MITES
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 165
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who signed and dated the patients' informed consent form obtained prior to any study specific examination.
- •Female or male patients between 18 and 65 years of age, at the time of signing the informed consent form
- •Patients with moderate-to-severe allergic rhinitis / rhino-conjunctivitis due to house dust mites for at least one year according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
- •Patients with or without well controlled mild-to-moderate asthma according to GINA guideline (Global Initiative for Asthma, 2017).
- •Forced expiratory volume (FEV1) in one second > 70 % of predicted normal value (only for asthmatic patients)
- •Sensitization to Dermatophagoides pteronyssinus, verified by:
- •a)positive skin prick test (wheal diameter = 3 mm and negative control < 2 mm and positive (histamine) control = 3 mm) and,
- •b)serum allergen-specific IgE to D. pteronyssinus = 0.7 kU/L (CAP EAST class = 2) and,
- •c) positive response to nasal provocation with D. pteronyssinus allergen extract (at least at the fourth concentration step)
- •Assumed compliance and ability of the patient to understand the patients´ diary and to follow the instructions of the study staff.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 165
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Previous immunotherapy with allergen extract of house dust mites (HDM) according to the homologous group of the Dermatophagoides genus, as defined in Annex 1 in the Guideline on allergen products: production and quality issues (EMEA/CHMP/BWP/304831) within the last 5 years
- •Patients co-sensitized to any pollen with clinical manifestations or co-allergies, whose allergic symptoms interfere with the conduct of the study (e. g. with the tNPT)
- •Allergy against other perennial allergens like animal epithelia
- •Patients co-sensitized to Lepidoglyphus destructor (LD), with IgE levels against LD higher than the double of the IgE levels against D. pteronyssinus
- •Simultaneous participation in other clinical trials
- •Simultaneous specific immunotherapy with other allergens
- •Participation in a clinical trial in the last three months before enrolment
- •Asthmatic patients with forced expiratory volume (FEV1) = 70 % of predicted normal value
- •Partly controlled or uncontrolled asthma according to GINA guideline (Global Initiative for Asthma, 2017)
- •Severe acute or chronic inflammatory or infectious diseases
- •Inflammations or lesions within the oral cavity (e. g. gingivitis) as well as gastroenteritis at randomization
- •Diseases of the immune system such as autoimmune and immune deficiencies (with exception to well controlled Hashimoto thyroiditis and type-1 diabetes mellitus)
- •Immunosuppressive therapy within 3 months prior screening
- •Chronic or acute diseases of the heart, kidney or liver with severe impairment of their function
- •Hypersensitivity to excipients of the IMP
- •Any severe or unstable lung disease (e. g. active tuberculosis, cystic fibrosis, COPD)
- •Chronic or severe acute diseases of nose or eyes
- •Irreversible secondary disorders of the target organs (e. g. emphysema, bronchiectasis)
- •Therapy with immunoglobulins
- •Completed or ongoing treatment with anti-IgE-antibody
- •Malignancy within the previous 5 years
- •Alcohol, drug, or medication abuse within the past year and/or during the study
- •Use of non-allowed medication (see section 8.3.1)
- •Contraindications for SPT
- •Contraindication for NPT
- •Patients with PNIF decrease = 20 % during tNPT after application of control solution at V0
- •Relationship or dependence with the sponsor and/or investigator
- •Legal incapacity
- •Patients who are jurisdictional or governmentally institutionalized
- •Serious systemic reactions to allergen-specific immunotherapy in the past
- •Active chronic urticaria
- •Active severe atopic eczema
- •Existing or intended pregnancy, lactation or inadequate contraceptive measures for woman with child-bearing potential or a positive pregnancy test at screening
- •Severe psychiatric, psychological, or neurological disorders; completed or ongoing long-term treatment with tranquilizers or psychactive drugs (including tricyclic antidepressants)
- •Risk of non-compliance by the patient with study procedures
研究者
相似试验
进行中（未招募）
1 期
CLINICAL TRIAL TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM GRASS POLLEN ALLERGYPatients with grass pollen related allergic rhinitis/rhino-conjunctivitis (with or without well controlled asthma).EUCTR2011-002301-29-ESROXALL Medicina España S.A.165
已完成
不适用
An Open-Label Phase I Dose-Escalation Study of Sorafenib Plus S-1 in Advanced Solid TumorsPER-015-10CureTech Ltd,7
进行中（未招募）
不适用
A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IDES IN CHRONIC KIDNEY DISEASE PATIENTSEUCTR2013-005417-13-SEHansa Medical AB
进行中（未招募）
1 期
A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IDES IN KIDNEY TRANSPLANTATIORemoval of anti-HLA antibodies in patients planned to undergo kidney transplantationEUCTR2014-000712-34-SEHansa Medical AB
进行中（未招募）
1 期
Allogeneic Donor Lymphocyte Infusions Combined with BlinatumomabSubjects with treatment-resistant mixed chimerism or MRD of CD19+ B-precursor ALL after allogeneic SCTMedDRA version: 20.0Level: LLTClassification code 10063621Term: Acute lymphoblastic leukaemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2017-002314-31-DEKlinikum der Universität München12